Sylogist Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Sylogist heeft een totaal eigen vermogen van CA$35.2M en een totale schuld van CA$19.0M, wat de schuld-eigenvermogensverhouding op 54.1% brengt. De totale activa en totale passiva bedragen respectievelijk CA$99.0M en CA$63.8M. De EBIT Sylogist is CA$4.1M waardoor de rentedekking 2.5 is. Het heeft contanten en kortetermijnbeleggingen van CA$13.3M.

Belangrijke informatie

54.1%

Verhouding schuld/eigen vermogen

CA$19.03m

Schuld

Rente dekkingsratio	2.5x
Contant	CA$13.33m
Aandelen	CA$35.17m
Totaal verplichtingen	CA$63.84m
Totaal activa	CA$99.01m

Recente financiële gezondheidsupdates

We Think Sylogist (TSE:SYZ) Can Stay On Top Of Its Debt

May 04

These 4 Measures Indicate That Sylogist (TSE:SYZ) Is Using Debt Reasonably Well

Oct 20

Recent updates

Sylogist Ltd. (TSE:SYZ) Shares Could Be 41% Below Their Intrinsic Value Estimate

Mar 27

Estimating The Intrinsic Value Of Sylogist Ltd. (TSE:SYZ)

Dec 16

Sylogist (TSE:SYZ) Has Affirmed Its Dividend Of CA$0.13

Nov 25

These 4 Measures Indicate That Sylogist (TSE:SYZ) Is Using Debt Reasonably Well

Oct 20

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CA$29.8M ) van SYZ } dekken niet de korte termijn passiva ( CA$54.8M ).

Langlopende schulden: De kortetermijnactiva SYZ ( CA$29.8M ) overtreffen de langetermijnschulden ( CA$9.0M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 16.2% ) SYZ wordt als voldoende beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van SYZ is de afgelopen 5 jaar gestegen van 0% naar 54.1%.

Schuldendekking: De schuld van SYZ wordt goed gedekt door de operationele kasstroom ( 58.6% ).

Rentedekking: De rentebetalingen van SYZ op haar schulden worden niet goed gedekt door EBIT ( 2.5 x dekking).

Sylogist Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Belangrijke informatie

Recente financiële gezondheidsupdates

We Think Sylogist (TSE:SYZ) Can Stay On Top Of Its Debt

These 4 Measures Indicate That Sylogist (TSE:SYZ) Is Using Debt Reasonably Well

Recent updates

Third quarter dividend of CA$0.01 announced

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Sylogist Ltd. Approves Dividend, Payable on December 11, 2024

New minor risk - Insider selling

Independent Director recently sold CA$108k worth of stock

Independent Chairman exercised options to buy CA$216k worth of stock.

Second quarter dividend of CA$0.01 announced

Second quarter 2024 earnings: EPS misses analyst expectations

Sylogist Ltd. Approves Dividend, Payable on September 11, 2024

Sylogist Ltd. to Report Q2, 2024 Results on Aug 08, 2024

Sylogist Ltd. Elects Aziz Benmalek as New Director

Consensus EPS estimates fall by 40%

First quarter dividend of CA$0.01 announced

Sylogist Ltd. Approves A Dividend, Payable on June 12, 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Sylogist Ltd. Approves A Dividend, Payable on June 12, 2024

Sylogist Ltd., Annual General Meeting, Jun 12, 2024

Full year 2023 earnings: EPS misses analyst expectations

Sylogist Ltd. to Report Q4, 2023 Results on Mar 14, 2024

Third quarter dividend of CA$0.01 announced

Sylogist Ltd. Declares Quarterly Dividend, Payable on March 13, 2024

Sylogist Ltd. Announces Board Appointments

Pinning Down Sylogist Ltd.'s (TSE:SYZ) P/S Is Difficult Right Now

Price target increased by 12% to CA$11.00

Upcoming dividend of CA$0.01 per share at 0.6% yield

Sylogist Ltd. Approves Dividend, Payable on December 13, 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations

Sylogist Ltd. to Report Q3, 2023 Results on Nov 09, 2023

Price target increased by 13% to CA$11.10

Sylogist Ltd. Announces Changes Management Changes

Upcoming dividend of CA$0.01 per share at 0.5% yield

Sylogist Ltd. Approves Dividend, Payable on September 13, 2023

Second quarter 2023 earnings released: CA$0.003 loss per share (vs CA$0.037 profit in 2Q 2022)

Sylogist Ltd. to Report Q2, 2023 Results on Aug 10, 2023

Now 20% undervalued

Now 20% undervalued

New major risk - Revenue and earnings growth

Sylogist (TSE:SYZ) Could Be Struggling To Allocate Capital

Upcoming dividend of CA$0.01 per share at 0.7% yield

Sylogist Ltd. Declares A Dividend, Payable on June 14, 2023

First quarter 2023 earnings released: EPS: CA$0.004 (vs CA$0.029 in 1Q 2022)

Sylogist Ltd., Annual General Meeting, Jun 21, 2023

Sylogist Ltd. to Report Q1, 2023 Results on May 11, 2023

Now 23% undervalued after recent price drop

President recently bought CA$105k worth of stock

Now 26% undervalued after recent price drop

Now 20% undervalued

Upcoming dividend of CA$0.01 per share at 0.7% yield

Sylogist Ltd. Declares Quarterly Dividend, Payable on March 15, 2023

Sylogist (TSE:SYZ) Is Reinvesting At Lower Rates Of Return

Now 21% undervalued after recent price drop

Is Sylogist Ltd. (TSE:SYZ) Trading At A 29% Discount?

Sylogist Ltd. Appoints Grant McLarnon as Chief Revenue Officer

President recently bought CA$136k worth of stock

Upcoming dividend of CA$0.01 per share

Sylogist Ltd. Announces Retirement of Dave Elder as Executive Vice President and Corporate Secretary

Should You Investigate Sylogist Ltd. (TSE:SYZ) At CA$4.76?

Price target decreased to CA$9.38

Sylogist Ltd. Approves Quarterly Dividend, Payable on December 14, 2022

Sylogist Ltd. to Report Q4, 2022 Results on Nov 14, 2022

Sylogist (TSE:SYZ) Is Paying Out A Dividend Of CA$0.125

Consensus EPS estimates increase by 40%

Sylogist Ltd. Approves Quarterly Dividend, Payable on September 14, 2022

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Sylogist Ltd. to Report Q3, 2022 Results on Aug 11, 2022

High number of new directors

Independent Director recently bought CA$73k worth of stock

What Is Sylogist Ltd.'s (TSE:SYZ) Share Price Doing?

Executive VP & Corporate Secretary recently bought CA$83k worth of stock

Sylogist (TSE:SYZ) Will Pay A Dividend Of CA$0.13

Consensus EPS estimates fall by 38%

Price target decreased to CA$14.44